ArticleJournal of clinical laboratory analysis2026
Validation of the Primerdesign Quantitative Allele Specific Amplification Kit for the Detection of JAK2V617F Mutation.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionJanus Kinase 2 (JAK2) is a tyrosine kinase involved in cellular signalling. A point mutation in codon 617 of JAK2 (JAK2V617F) causes a gain-of-function effect that stimulates proliferation of myeloid cells. The aim of this study was to evaluate the Primerdesign quantitative allele-specific amplification (Quasa) kit for the detection of JAK2V617F.
methodsSpecimens previously evaluated using real-time PCR with melting curve analysis were analysed using the Quasa kit on the Bio-Rad CFX 96 platform. Results of the two PCR tests were compared to evaluate the accuracy of the kit. For intra-assay precision, samples were analysed in duplicate on the same run, and for inter-assay variation, the same known samples were tested on three non-consecutive days. The analytical sensitivity and quantitative analysis of the assay were determined using the World Health Organization (WHO) 1st International Reference Panel for Genomic JAK2V617F (United Kingdom Official Medicines Control Laboratory) and the United Kingdom National External Quality Assessment Service (UK NEQAS) results of their JAK2 p.val617phe (V617F) Mutation Status Programme.
resultsConcordance of the qualitative test results between the test methods was 100%. Precision experiments confirmed repeatability and reproducibility. Analytical sensitivity was confirmed at 0.1%.
conclusionThe PrimerDesign Quasa kit for the detection of JAK2V617F is a sensitive and reliable assay that yields reproducible qualitative results. The kit is commercially available and has, in addition, the potential for quantitative analysis when samples are analysed in duplicate. This kit assay validation may be valuable to laboratories offering or interested in offering JAK2V617F mutational testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.